Advertisement

CNS Drugs

, Volume 23, Issue 5, pp 427–452 | Cite as

Mirtazapine

A Review of its Use in Major Depression and Other Psychiatric Disorders
  • Katherine F. Croom
  • Caroline M. Perry
  • Greg L. Plosker
Adis Drug Evaluation

Summary

Abstract

Mirtazapine (Remeron®, Zispin®) is a noradrenergic and specific serotonergic antidepressant (NaSSA) that is approved in many counties for use in the treatment of major depression. Monotherapy with mirtazapine 15—45mg/day leads to rapid and sustained improvements in depressive symptoms in patients with major depression, including the elderly. It is as effective as other antidepressants and may have a more rapid onset of action than selective serotonin reuptake inhibitors (SSRIs). Furthermore, it may also have a higher sustained remission rate than amitriptyline. Preliminary data suggest that mirtazapine may also be effective in the treatment of anxiety disorders (including post-traumatic stress disorder, panic disorder and social anxiety disorder), obsessive-compulsive disorder, undifferentiated somatoform disorder and, as add-on therapy, in schizophrenia, although large, well designed trials are needed to confirm these findings. Mirtazapine is generally well tolerated in patients with depression. In conclusion, mirtazapine is an effective antidepressant for the treatment of major depression and also has the potential to be of use in other psychiatric indications.

Pharmacological Properties

The antidepressant activity of mirtazapine, an NaSSA agent, is thought to result from a combination of noradrenergic and serotonergic effects, with the latter specifically involving enhancement of serotonin 5-HT1 receptor-mediated effects. It acts as an antagonist at central α2-adrenergic autoreceptors and heteroreceptors, andpostsynaptic 5-HT2 and 5-HT3 receptors. Mirtazapine has low affinity for central and peripheral dopaminergic receptors, but is a potent antagonist of histamine H1 receptors and a moderate antagonist at muscarinic receptors. Mirtazapine improves sleep efficiency and continuity, and does not suppress rapid eye movement sleep.

Mirtazapine is absorbed rapidly after oral administration, with peak plasma concentrations achieved within 2 hours. Food has no clinically relevant effect on absorption. Mirtazapine displays linear pharmacokinetics over the therapeutic dosage range, and steady state is reached after ≈5 days. Mirtazapine is extensively metabolized, principally via cytochrome P450 (CYP) isoenzymes CYP3A4, CYP2D6 and CYP1A2. The elimination half-life of mirtazapine is 20—40 hours. Mirtazapine is a racemate and the enantiomers display differing pharmacokinetic and pharmacodynamic properties; both enantiomers contribute to the pharmacodynamic effects of mirtazapine.

Therapeutic Efficacy

A number of well designed trials have demonstrated the efficacy of mirtazapine in the treatment of patients with moderate to severe major depression. Mirtazapine was more effective than placebo at relieving the symptoms of depression in short-term studies and effectively prevented relapse for up to 1 year. In short-term comparisons with tricyclic antidepressants (TCAs) and related drugs, mirtazapine howed antidepressant efficacy similar to that of comparator agents such as amitriptyline and trazodone. The proportion of patients classified as Hamilton Depression Rating Scale (HAM-D) responders in comparisons with amitriptyline ranged from 53% to 72% with mirtazapine and from 48% to 72% with amitriptyline. Mirtazapine also had a higher sustained remission rate than amitriptyline in a long-term, double-blind continuation study. In comparisons with trazodone, HAM-D response rates were 51—61% with mirtazapine and 41—51% with trazodone. In comparisons with SSRIs over 6—24 weeks, mirtazapine showed similar anti-depressant efficacy to citalopram (single study), fluoxetine, paroxetine and sertra-line (single study). Overall, the proportion of patients classified as HAM-D responders at endpoint in these trials was 50—73% for mirtazapine, 45—71% forfluoxetine, 50—56% for paroxetine and 52% for sertraline (HAM-D response data not available for citalopram). Mirtazapine was as effective as venlafaxine in the treatment of hospitalized patients with severe depression with melancholic features.

In a meta-analysis comparing 12 newer-generation antidepressants, mirtazapine emerged as one of four agents deemed to have superior efficacy in the acute-phase treatment of major depression. Other meta-analyses of trials comparing mirtazapine with SSRIs found that mirtazapine was associated with an earlier onset of action than SSRIs.

The efficacy of mirtazapine has been demonstrated in patients treated in hospital, outpatient and primary care settings. Efficacy has been shown in elderly patients, patients who have not responded to SSRIs and in those with symptoms of anxiety or insomnia.

A number of smaller trials (n < 100) have also shown promising results with mirtazapine in other psychiatric disorders, including post-stroke depression, post-traumatic stress disorder, panic disorder, social anxiety disorder, obsessive-compulsive disorder, undifferentiated somatoform disorder and (as add-on therapy) in schizophrenia. Other small studies showed promising results with mirtazapine in patients with major depression and concomitant conditions such as Parkinson’s disease, cancer or fibromyalgia syndrome.

Tolerability

Mirtazapine was generally well tolerated in clinical trials in patients with major depression. Events occurring at a significantly higher incidence with mirtazapine than with placebo included drowsiness, excessive sedation, increased appetite, weight gain and dry mouth. The pattern of adverse events in elderly patients was similar to that in the overall population. At therapeutic doses, mirtazapine had no significant effect on blood pressure or heart rate and had a low potential for inducing seizures. Mirtazapine generally had no adverse effects on sexual function, and switching patients with SSRI-induced sexual dysfunction to mirtazapine improved sexual function. Compared with TCAs and trazodone, mirtazapine was generally associated with a lower incidence of dizziness, tremor and anticholinergic adverse events. Compared with SSRIs, mirtazapine was associated with less insomnia and nausea, but with more weight gain, dry mouth, fatigue and excessive somnolence.

Keywords

Fluoxetine Paroxetine Venlafaxine Social Anxiety Disorder Mirtazapine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    British Association for Psychopharmacology. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines [online]. Available from URL: http://www.bap.org.uk [Accessed 2008 May 27]
  2. 2.
    Andrews G, Poulton R, Skoog I. Lifetime risk of depression: restricted to a minority or waiting for most? Br J Psychiatry 2005; 187: 495–6PubMedCrossRefGoogle Scholar
  3. 3.
    Waraich P, Goldner EM, Somers JM, et al. Prevalence and incidence studies of mood disorders: a systematic review of the literature. Can J Psychiatry 2004; 49(2): 124–38PubMedGoogle Scholar
  4. 4.
    American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder. 2nd edition [online]. Available from URL: http://www.psychiatryonline.com [Accessed 2008 May 27]
  5. 5.
    De Boer T, Ruigt GSF, Berendsen HHG. The alpha2-selective adrenoceptor antagonist Org 3770 (mirtazapine, Remeron) enhances noradrenergic and serotonergic transmission. Hum Psychopharmacol 1995; 10Suppl. 2: S107–18CrossRefGoogle Scholar
  6. 6.
    Organon Laboratories Ltd. Remeron SolTab 15, 30 and 45 mg: summary of product characteristics (EC) [online]. Available from URL: http://www.organon.com [Accessed 2008 Apr 29]
  7. 7.
    Organon USA Inc. Remeron (mirtazapine) tablets: US prescribing information [online]. Available from URL: http://www.organon-usa.com [Accessed 2008 Apr 4]
  8. 8.
    Holm KJ, Markham A. Mirtazapine: a review of its use in major depression. Drugs 1999 Apr; 57(4): 607–31PubMedCrossRefGoogle Scholar
  9. 9.
    Haddjeri N, Blier P, De Montigny C. Acute and long-term actions of the antidepressant drug mirtazapine on central 5-HT neurotransmission. J Affect Disord 1998; 51(3): 255–66PubMedCrossRefGoogle Scholar
  10. 10.
    de Montigny C, Haddjeri N, Mongeau R, et al. The effects of mirtazapine on the interactions between central noradrenergic and serotonergic systems. CNS Drugs 1995; 4 Suppl. 1: 13–7CrossRefGoogle Scholar
  11. 11.
    Organon USA Inc. RemeronSolTab® (mirtazapine) orally disintegrating tablets: US prescribing information [online]. Available from URL: http://www.remeronsoltab.com [Accessed 2009 Mar 12]
  12. 12.
    Pinder RM. The pharmacologic rationale for the clinical use of antidepressants. J Clin Psychiatry 1997; 58(11): 501–8PubMedCrossRefGoogle Scholar
  13. 13.
    McGrath C, Burrows N. Neurochemical effects of enantiomers of mirtazapine in normal rats. Eur J Pharmacol 1998; 256: 121–6CrossRefGoogle Scholar
  14. 14.
    Garcia-Sevilla JA, Ventayol P, Pérez V, et al. Regulation of platelet alpha 2A-adrenoceptors, Gi proteins and receptor kinases in major depression: effects of mirtazapine treatment. Neuropsychopharmacology 2004 Mar; 29(3): 580–8PubMedCrossRefGoogle Scholar
  15. 15.
    Delgado PL, Moreno FA, Onate L, et al. Sequential catecholamine and serotonin depletion in mirtazapine-treated depressed patients. Int J Neuropsychopharmacol 2002 Mar; 5(1): 63–6PubMedCrossRefGoogle Scholar
  16. 16.
    Pinder RM. Designing a new generation of antidepressant drugs. Acta Psychiatr Scand 1997; 96 Suppl. 391: 7–13CrossRefGoogle Scholar
  17. 17.
    Aslan S, Isik E, Cosar B. The effects of mirtazapine on sleep: a placebo controlled, double-blind study in young healthy volunteers. Sleep 2002 Sep 15; 25(6): 677–9PubMedGoogle Scholar
  18. 18.
    Shen J, Chung SA, Kayumov L, et al. Polysomnographic and symptomatological analyses of major depressive disorder patients treated with mirtazapine. Can J Psychiatry 2006 Jan; 51(1): 27–34PubMedGoogle Scholar
  19. 19.
    Winokur A, DeMartinis III NA, McNally DP, et al. Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia. J Clin Psychiatry 2003 Oct; 64(10): 1224–9PubMedCrossRefGoogle Scholar
  20. 20.
    Wingen M, Bothmer J, Langer S, et al. Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine, and placebo: a crossover trial. J Clin Psychiatry 2005 Apr; 66(4): 436–43PubMedCrossRefGoogle Scholar
  21. 21.
    Ridout F, Meadows R, Johnsen S, et al. A placebo controlled investigation into the effects of paroxetine and mirtazapine on measures related to car driving performance. Hum Psychopharmacol 2003 Jun; 18(4): 261–9PubMedCrossRefGoogle Scholar
  22. 22.
    Ramaekers JG, Muntjewerff ND, Van Veggel LMA, et al. Effects of nocturnal doses of mirtazapine and mianserin on sleep and on daytime psychomotor and driving performance in young, healthy volunteers. Hum Psychopharmacol 1998; 13: S87–97CrossRefGoogle Scholar
  23. 23.
    Schüle C, Baghai T, Rackwitz C, et al. Influence of mirtazapine on urinary free cortisol excretion in depressed patients. Psychiatry Res 2003 Oct 15; 120(3): 257–64PubMedCrossRefGoogle Scholar
  24. 24.
    Laakmann G, Schule C, Baghai T, et al. Effects of mirtazapine on growth hormone, prolactin, and cortisol secretion in healthy male subjects. Psychoneuroendocrinology 1999 Oct 1; 24: 769–84PubMedCrossRefGoogle Scholar
  25. 25.
    Schüle C, Baghai T, Goy J, et al. The influence of mirtazapine on anterior pituitary hormone secretion in healthy male subjects. Psychopharmacology (Berl) 2002 Aug; 163(1): 95–101CrossRefGoogle Scholar
  26. 26.
    Laakmann G, Hennig J, Baghai T, et al. Mirtazapine acutely inhibits salivary cortisol concentrations in depressed patients. Ann N Y Acad Sci 2004 Dec; 1032: 279–82PubMedCrossRefGoogle Scholar
  27. 27.
    Brunnauer A, Laux G, Geiger E, et al. Antidepressants and driving ability: results from a clinical study. J Clin Psychiatry 2006 Nov; 67(11): 1776–81PubMedCrossRefGoogle Scholar
  28. 28.
    Wingen M, Langer S, Ramaekers JG. Verbal memory performance during subchronic challenge with a selective serotonergic and a mixed action antidepressant. Hum Psychopharmacol 2006 Oct; 21(7): 473–9PubMedCrossRefGoogle Scholar
  29. 29.
    Laimer M, Kramer-Reinstadler K, Rauchenzauner M, et al. Effect of mirtazapine treatment on body composition and metabolism. J Clin Psychiatry 2006 Mar; 67(3): 421–4PubMedCrossRefGoogle Scholar
  30. 30.
    Kraus T, Haack M, Schuld A, et al. Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine. Pharmacopsychiatry 2002 Nov; 35(6): 220–5PubMedCrossRefGoogle Scholar
  31. 31.
    Nicholas LM, Ford AL, Esposito SM, et al. The effects of mirtazapine on plasma lipid profiles in healthy subjects. J Clin Psychiatry 2003 Aug; 64(8): 883–9PubMedCrossRefGoogle Scholar
  32. 32.
    Tulen JHM, Bruijn JA, de Man KJ, et al. Cardiovascular variability in major depressive disorder and effects of imipramine or mirtazapine (Org 3770). J Clin Psychopharmacol 1996; 16(2): 135–45PubMedCrossRefGoogle Scholar
  33. 33.
    Arnold P, Vuadens P, Kuntzer T, et al. Mirtazapine decreases the pain feeling in healthy participants. Clin J Pain 2008 Feb; 24(2): 116–9PubMedCrossRefGoogle Scholar
  34. 34.
    Münchau A, Langosch JM, Gerschlager W, et al. Mirtazapine increases cortical excitability in healthy controls and epilepsy patients with major depression. J Neurol Neurosurg Psychiatry 2005 Apr; 76(4): 527–33PubMedCrossRefGoogle Scholar
  35. 35.
    Neu P, Schwertfeger N, Schlattmann P, et al. Cerebrovascular reactivity following administration of mirtazapine in healthy probands: a randomized, placebo controlled double-blind clinical study. J Psychiatr Res 2006 Jun; 40(4): 349–52PubMedCrossRefGoogle Scholar
  36. 36.
    Waldinger MD, Zwinderman AH, Olivier B. Anti-depressants and ejaculation: a double-blind, randomized, fixed-dose study with mirtazapine and paroxetine. J Clin Psychopharmacol 2003 Oct; 23(5): 467–70PubMedCrossRefGoogle Scholar
  37. 37.
    van den Heuvel MW, Kleijn HJ, Peeters PAM. Bioequivalence trial of orally distintegrating mirtazapine tablets and conventional oral mirtazapine tablets in healthy volunteers. Clin Drug Invest 2001; 21(6): 437–42CrossRefGoogle Scholar
  38. 38.
    Delbressine LP, Moonen ME, Kaspersen FM, et al. Pharmacokinetics and biotransformation of mirtazapine in human volunteers. Clin Drug Invest 1998; 15(1): 45–55CrossRefGoogle Scholar
  39. 39.
    Timmer CJ, Sitsen JMA, Delbressine LP. Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet 2000 Jun; 38(6): 461–74PubMedCrossRefGoogle Scholar
  40. 40.
    Voortman G, Paanakker JE. Bioavailability of mirtazapine from Remeron® tablets after single and multiple oral dosing. Hum Psychopharmacol 1995; 10: S83–96CrossRefGoogle Scholar
  41. 41.
    Timmer CJ, Lohmann AAM, Mink CPA. Pharmacokinetic dose-proportionality study at steady state of mirtazapine from Remeron® tablets. Hum Psychopharmacol 1995; 10: S97–106CrossRefGoogle Scholar
  42. 42.
    Kristensen JH, Ilett KF, Rampono J, et al. Transfer of the antidepressant mirtazapine into breast milk. Br J Clin Pharmacol 2007 Mar; 63(3): 322–7PubMedCrossRefGoogle Scholar
  43. 43.
    Störmer E, Von Moltke LL, Shader RI, et al. Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metab Dispos 2000; 28(10): 1168–75PubMedGoogle Scholar
  44. 44.
    Reis M, Prochazka J, Sitsen A, et al. Inter- and intraindividual pharmacokinetic variations of mirtazapine and its N-demethyl metabolite in patients treated for major depressive disorder: a 6-month therapeutic drug monitoring study. Ther Drug Monit 2005 Aug; 27(4): 469–77PubMedCrossRefGoogle Scholar
  45. 45.
    Grasmäder K, Verwohlt PL, Kühn KU, et al. Population pharmacokinetic analysis of mirtazapine. Eur J Clin Pharmacol 2004 Sep; 60(7): 473–80PubMedCrossRefGoogle Scholar
  46. 46.
    Kirchheiner J, Henckel HB, Meineke I, et al. Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers. J Clin Psychopharmacol 2004 Dec; 24(6): 647–52PubMedCrossRefGoogle Scholar
  47. 47.
    Dodd S, Boulton DW, Burrows GD, et al. In vitro metabolism of mirtazapine enantiomers by human cytochrome P450 enzymes. Hum Psychopharmacol 2001; 16(7): 541–4PubMedCrossRefGoogle Scholar
  48. 48.
    Brockmöller J, Meineke I, Kirchheiner J. Pharmacokinetics of mirtazapine: enantioselective effects of the CYP2D6 ultra rapid metabolizer genotype and correlation with adverse effects. Clin Pharmacol Ther 2007 May; 81(5): 699–707PubMedCrossRefGoogle Scholar
  49. 49.
    Peeters P, Brett M, Heuvel MV, et al. Pharmacokinetics and safety of mirtazapine in Caucasian and Japanese young healthy male volunteers. Clin Pharmacol Ther 2004 Feb; 75(2): 36CrossRefGoogle Scholar
  50. 50.
    Timmer CJ, Paanakker JE, Van Hal HJM. Pharmacokinetics of mirtazapine from orally administered tablets: influence of gender, age and treatment regimen. Hum Psychopharmacol 1996; 11(6): 497–509CrossRefGoogle Scholar
  51. 51.
    Bengtsson F, Höglund P, Timmer C, et al. Mirtazapine oral single dose kinetics in patients with different degrees of renal failure. Hum Psychopharmacol 1998; 13(5): 357–65CrossRefGoogle Scholar
  52. 52.
    Sitsen JM, Maris FA, Timmer CJ. Concomitant use of mirtazapine and cimetidine: a drug-drug interaction study in healthy male subjects. Eur J Clin Pharmacol 2000 Aug; 56(5): 389–94PubMedCrossRefGoogle Scholar
  53. 53.
    Spaans E, van den Heuvel MW, Schnabel PG, et al. Concomitant use of mirtazapine and phenytoin: a drug-drug interaction study in healthy male subjects. Eur J Clin Pharmacol 2002 Sep; 58(6): 423–9PubMedCrossRefGoogle Scholar
  54. 54.
    Sennef C, Timmer CJ, Sitsen JM. Mirtazapine in combination with amitriptyline: a drug-drug interaction study in healthy subjects. Hum Psychopharmacol 2003 Mar; 18(2): 91–101PubMedCrossRefGoogle Scholar
  55. 55.
    Ruwe FJL, Smulders RA, Kleijn HJ, et al. Mirtazapine and paroxetine: a drug-drug interaction study in healthy subjects. Hum Psychopharmacol 2001; 16(6): 449–59PubMedCrossRefGoogle Scholar
  56. 56.
    Sitsen JM, Voortman G, Timmer CJ. Pharmacokinetics of mirtazapine and lithium in healthy male subjects. J Psychopharmacol 2000 Jun; 14(2): 172–6PubMedCrossRefGoogle Scholar
  57. 57.
    Loonen AJ, Doorschot CH, Oostelbos MC, et al. Lack of drug interactions between mirtazapine and risperidone in psychiatric patients: a pilot study. Eur Neuropsychopharmacol 1999 Dec; 10(1): 51–7PubMedCrossRefGoogle Scholar
  58. 58.
    Anttila AK, Rasanen L, Leinonen EV. Fluvoxamine augmentation increases serum mirtazapine concentrations three-to fourfold. Ann Pharmacother 2001 Oct; 35(10): 1221–3PubMedCrossRefGoogle Scholar
  59. 59.
    Lind AB, Reis M, Bengtsson F, et al. Steady-state concentrations of mirtazapine, N-desmethylmirtazapine, 8-hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour. Clin Pharmacokinet 2009; 48(1): 63–70PubMedCrossRefGoogle Scholar
  60. 60.
    Bruijn JA, Moleman P, Mulder PGH, et al. A doubleblind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients. Psychopharmacol 1996; 127: 231–7Google Scholar
  61. 61.
    Davis R, Wilde MI. Mirtazapine: a review of its pharmacology and therapeutic potential in the management of major depression. CNS Drugs 1996 May; 5(5): 389–402CrossRefGoogle Scholar
  62. 62.
    Kasper S. Clinical efficacy of mirtazapine: a review of meta-analyses of pooled data. Int Clin Psychopharmacol 1995; 10 Suppl. 4: 25–35CrossRefGoogle Scholar
  63. 63.
    Stahl S, Zivkov M, Reimitz PE, et al. Meta-analysis of randomized, double-blind, placebo-controlled, efficacy and safety studies of mirtazapine versus amitriptyline in major depression. Acta Pychiatr Scand Suppl 1997; 96Suppl. 391: 22–30CrossRefGoogle Scholar
  64. 64.
    Fawcett J, Barkin RL. A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety. J Clin Psychiatry 1998 Mar; 59: 123–7PubMedCrossRefGoogle Scholar
  65. 65.
    Bech P. Meta-analysis of placebo-controlled trials with mirtazapine using the core items of the Hamilton Depression Scale as evidence of a pure antidepressive effect in the short-term treatment of major depression. Int J Neuropsychopharmacol 2001 Dec; 4(4): 337–45PubMedCrossRefGoogle Scholar
  66. 66.
    Van Oers HJJ, Simmons J, van der Meulen EA. Longitudinal meta-analysis of the surrogate suicide items of the Hamilton and/or the Montgomery-Asberg rating scales comparing mirtazapine versus placebo [abstract no. NR292 plus poster]. 159th Annual Meeting of the American Psychiatric Association; 2006 May 20—25; Toronto (ON)Google Scholar
  67. 67.
    Kasper S, Montgomery SA, Möller HJ, et al. Longitudinal analysis of the suicidal behaviour risk in short-term placebo-controlled studies of mirtazapine in major depressive disorder. World J Biol Psychiatry. Epub 2007 Oct 29Google Scholar
  68. 68.
    Thase ME, Nierenberg AA, Keller MB, et al. Efficacy of mirtazapine for prevention of depressive relapse: a placebo-controlled double-blind trial of recently remitted high-risk patients. J Clin Psychiatry 2001 Oct; 62(10): 782–8PubMedCrossRefGoogle Scholar
  69. 69.
    Kinoshita T. A double-blind, placebo-controlled study of a new antidepressant, mirtazapine, in depressed patients [abstract]. Jpn J Clin Psychopharmacol 2009; 12(2): 289–306Google Scholar
  70. 70.
    Kinoshita T. Long-term clinical study of a new anti-depressant, mirtazapine, in depressed patients. Jpn J Clin Psychopharmacol 2009; 12: 503–20Google Scholar
  71. 71.
    Bremner JD. A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression. J Clin Psychiatry 1995; 56(11): 519–25PubMedGoogle Scholar
  72. 72.
    Hoyberg OJ, Maragakis B, Mullin J, et al. A double-blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients. Acta Psychiatr Scand 1996; 93: 184–90PubMedCrossRefGoogle Scholar
  73. 73.
    Mullin J, Lodge A, Bennie E, et al. A multicentre, double-blind, amitriptyline-controlled study of mirtazapine in patients with major depression. J Psychopharmacol 1996; 10(3): 235–40PubMedCrossRefGoogle Scholar
  74. 74.
    Smith WT, Glaudin V, Panagides J, et al. Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder. Psychopharmacol Bull 1990; 26(2): 191–6Google Scholar
  75. 75.
    Zivkov M, de Jongh GD. Org 3770 versus amitriptyline: a 6-week randomized double-blind multicentre trial in hospitalized depressed patients. Hum Psychopharmacol 1995; 10: 173–80CrossRefGoogle Scholar
  76. 76.
    Richou H, Ruimy P, Charbaut J, et al. A multicentre, double-blind, clomipramine-controlled efficacy and safety study of Org 3770. Hum Psychopharmacol 1995; 10: 263–71CrossRefGoogle Scholar
  77. 77.
    Halikas JA. Org 3770 (mirtazapine) versus trazodone: a placebo controlled trial in depressed elderly patients. Hum Psychopharmacol 1995; 10: S125–33CrossRefGoogle Scholar
  78. 78.
    van Moffaert M, de Wilde J, Vereecken A, et al. Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalized patients with major depression. Int Clin Psychopharmacol 1995; 10(1): 3–9PubMedCrossRefGoogle Scholar
  79. 79.
    Montgomery SA, Reimitz PE, Zivkov M. Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind placebo-controlled study. Int Clin Psychopharmacol 1998; 13(2): 63–73PubMedCrossRefGoogle Scholar
  80. 80.
    Bruijn JA, Moleman P, Mulder PG, et al. Comparison of 2 treatment strategies for depressed inpatients: imipramine and lithium addition or mirtazapine and lithium addition. J Clin Psychiatry 1998 Dec; 59(12): 657–63PubMedCrossRefGoogle Scholar
  81. 81.
    Leinonen E, Skarstein J, Behnke K, et al. Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group. Int Clin Psychopharmacol 1999 Nov; 14(6): 329–37CrossRefGoogle Scholar
  82. 82.
    Hong CJ, Hu WH, Chen CC, et al. A double-blind, randomized, group-comparative study of the tolerability and efficacy of 6 weeks’ treatment with mirtazapine or fluoxetine in depressed Chinese patients. J Clin Psychiatry 2003 Aug; 64(8): 921–6PubMedCrossRefGoogle Scholar
  83. 83.
    Versiani M, Moreno R, Ramakers-van Moorsel CJ, et al. Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients. CNS Drugs 2005; 19(2): 137–46PubMedCrossRefGoogle Scholar
  84. 84.
    Wheatley DP, van Moffaert M, Timmerman L, et al. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. J Clin Psychiatry 1998; 59(6): 306–12PubMedCrossRefGoogle Scholar
  85. 85.
    Benkert O, Szegedi A, Kohnen R. Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry 2000 Sep; 61(9): 656–63PubMedCrossRefGoogle Scholar
  86. 86.
    Schatzberg AF, Kremer C, Rodrigues HE, et al. Doubleblind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J Geriatr Psychiatry 2002; 10(5): 541–50PubMedGoogle Scholar
  87. 87.
    Wade A, Crawford GM, Angus M, et al. A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care. Int Clin Psychopharmacol 2003 May; 18(3): 133–41PubMedGoogle Scholar
  88. 88.
    Thase M, Kremer C, Rodrigues H. Mirtazapine versus sertraline after SSRI non-response [abstract no. P.6.010]. Eur Neuropsychopharmacol 2001 Oct; 11 Suppl. 3: 342CrossRefGoogle Scholar
  89. 89.
    Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation anti-depressants: a multiple-treatments meta-analysis. Lancet 2009; 373: 746–58PubMedCrossRefGoogle Scholar
  90. 90.
    Quitkin FM, Taylor BP, Kremer C. Does mirtazapine have a more rapid onset than SSRIs? J Clin Psychiatry 2001 May; 62(5): 358–61PubMedCrossRefGoogle Scholar
  91. 91.
    Watanabe N, Omori IM, Nakagawa A, et al. Mirtazapine versus other antidepressants in the acute-phase treatment of adults with major depression: systematic review and meta-analysis. J Clin Psychiatry 2008 Sep; 69(9): 1404–15PubMedCrossRefGoogle Scholar
  92. 92.
    van Willigenburg APP, Heukels AJ, Janssens CJJG, et al. Mirtazapine versus SSRIs: a meta-analysis on the onset of antidepressant activity in more than 2500 patients with major depression [abstract no. 6241]. World J Biol Psych 2004; 5Suppl. 1: 93Google Scholar
  93. 93.
    Barilla E, Jan Schutte A, Van Der Flier S, et al. Factor analysis of the onset of therapeutic effect of mirtazapine vs SSRIs: a meta-analysis on data of more than 2500 patients [abstract no. 6240]. World J Biol Psych 2004; 5Suppl. 1: 93Google Scholar
  94. 94.
    Behnke K, Sogaard J, Martin S, et al. Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study. J Clin Psychopharmacol 2003 Aug; 23(4): 358–64PubMedCrossRefGoogle Scholar
  95. 95.
    Guelfi JD, Ansseau M, Timmerman L, et al. Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features. J Clin Psychopharmacol 2001 Aug; 21(4): 425–31PubMedCrossRefGoogle Scholar
  96. 96.
    Van Hensbeek EJAM, Van Oers HJJ, Schutte AJ. Mirtazapine has similar short- and long-term efficacy compared to venlafaxine. Eur Neuropsychopharmacol 2001 Oct; 11Suppl. 3: 186–7CrossRefGoogle Scholar
  97. 97.
    Benkert O, Szegedi A, Philipp M, et al. Mirtazapine orally disintegrating tablets versus venlafaxine extended release: a double-blind, randomized multicenter trial comparing the onset of antidepressant response in patients with major depressive disorder. J Clin Psychopharmacol 2006 Feb; 26(1): 75–8PubMedCrossRefGoogle Scholar
  98. 98.
    Lee IS, Chung SK, Lee SY, et al. Mirtazapine versus venlafaxine for the treatment of depressive and physical symptoms in major depressive disorder [abstract no. NR11 plus poster]. 160th Annual Meeting of the American Psychiatric Association; 2007 May 19—24; San Diego (CA)Google Scholar
  99. 99.
    Kasper S, Zivkov M, Rocs KCB, et al. Pharmacological treatment of severely depressed patients: a meta-analysis comparing efficacy of mirtazapine and amitriptyline. Eur Neuropsychopharmacol 1997; 7: 115–24PubMedCrossRefGoogle Scholar
  100. 100.
    Fava M, Rush AJ, Wisniewski SR, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry 2006 Jul; 163(7): 1161–72PubMedCrossRefGoogle Scholar
  101. 101.
    McGrath PJ, Stewart JW, Fava M, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry 2006 Sep; 163(9): 1531–41PubMedCrossRefGoogle Scholar
  102. 102.
    Niedermaier N, Bohrer E, Schulte K, et al. Prevention and treatment of poststroke depression with mirtazapine in patients with acute stroke. J Clin Psychiatry 2004 Dec; 65(12): 1619–23PubMedCrossRefGoogle Scholar
  103. 103.
    Kim S-W, Shin I-S, Kim J-M, et al. Effectiveness of mirtazapine for nausea and insomnia in cancer patients with depression. Psychiatry Clin Neurosci 2008; 62: 75–83PubMedCrossRefGoogle Scholar
  104. 104.
    Ersoy MA, Noyan AM, Elbi H. An open-label long-term naturalistic study of mirtazapine treatment for depression in cancer patients. Clin Drug Invest 2008; 28(2): 113–20CrossRefGoogle Scholar
  105. 105.
    Weiser R, Hernadez-Rojas J, Flores J, et al. Efficacy, tolerability and safety of mirtazapine in the treatment of major depressive disorder due to Parkinson’s disease [abstract no. P575]. Mov Disord 2004 Jun 14; 19 Suppl. 9: 205Google Scholar
  106. 106.
    Erhan E, Yegul I, Pirim A, et al. A double-blind trial comparing mirtazapine with placebo in the treatment of fibromyalgia patients with major depressive disorder [abstract no. 621-P227]. 11th World Congress on Pain; 2005 Aug 21—26; Sydney (NSW)Google Scholar
  107. 107.
    Davidson JR, Weisler RH, Butterfield MI, et al. Mirtazapine vs. placebo in posttraumatic stress disorder: a pilot trial. Biol Psychiatry 2003 Jan 15; 53(2): 188–91Google Scholar
  108. 108.
    Chung MY, Min KH, Jun YJ, et al. Efficacy and tolerability of mirtazapine and sertraline in Korean veterans with posttraumatic stress disorder: a randomized open label trial. Hum Psychopharmacol 2004 Oct; 19(7): 489–94PubMedCrossRefGoogle Scholar
  109. 109.
    Ribeiro L, Busnello JV, Kauer-Sant’Anna M, et al. Mirtazapine versus fluoxetine in the treatment of panic disorder. Braz J Med Biol Res 2001 Oct; 34(10): 1303–7PubMedCrossRefGoogle Scholar
  110. 110.
    Boshuisen ML, Slaap BR, Vester-Blokland ED, et al. The effect of mirtazapine in panic disorder: an open label pilot study with a single-blind placebo run-in period. Int Clin Psychopharmacol 2001 Nov; 16(6): 363–8PubMedCrossRefGoogle Scholar
  111. 111.
    Muehlbacher M, Nickel MK, Nickel C, et al. Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2005 Dec; 25(6): 580–3PubMedCrossRefGoogle Scholar
  112. 112.
    Koran LM, Gamel NN, Choung HW, et al. Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation. J Clin Psychiatry 2005 Apr; 66(4): 515–20PubMedCrossRefGoogle Scholar
  113. 113.
    Pallanti S, Quercioli L, Bruscoli M. Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study. J Clin Psychiatry 2004 Oct; 65(10): 1394–9PubMedCrossRefGoogle Scholar
  114. 114.
    Han C, Pae CU, Lee BH, et al. Venlafaxine versus mirtazapine in the treatment of undifferentiated somatoform disorder: a 12-week prospective, open-label, randomized, parallel-group trial. Clin Drug Invest 2008; 28(4): 251–61CrossRefGoogle Scholar
  115. 115.
    Berk M, Ichim C, Brook S. Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. Int Clin Psychopharmacol 2001 Mar; 16(2): 87–92PubMedCrossRefGoogle Scholar
  116. 116.
    Zoccali R, Muscatello MR, Cedro C, et al. The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double-blind, placebo-controlled study. Int Clin Psychopharmacol 2004 Mar; 19(2): 71–6PubMedCrossRefGoogle Scholar
  117. 117.
    Joffe G, Terevnikov V, Joffe M, et al. Add-on mirtazapine enhances antipsychotic effect of first generation anti-psychotics in schizophrenia: a double-blind, randomized, placebo-controlled trial. Schizophr Res 2009 Mar; 108(1—3): 245–51PubMedCrossRefGoogle Scholar
  118. 118.
    Brown MC, Nimmerrichter AA, Guest JF. Cost-effectiveness of mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in Austria. Eur J Psychiatry 1999 Jul; 14(4): 230–44CrossRefGoogle Scholar
  119. 119.
    Brown MCJ, Van Loon JMT, Guest JF. Cost-effectiveness of mirtazapine relative to amitriptyline in the treatment of moderate and severe depression in France. Eur J Psychiatry 1999; 13(4): 197–208Google Scholar
  120. 120.
    Brown MCJ, Van Loon JMT, Guest JF. Cost-effectiveness of mirtazapine relative to fluoxetine in the treatment of moderate and severe depression in France. Eur J Psychiatry 2000; 14(1): 15–25Google Scholar
  121. 121.
    Norinder A, Nordling S. Treatment of depression and cost efficiency: the cost of a tablet is a poor indicator seen from a socioeconomic perspective. Lakartidningen 2000 Apr 5; 97(14): 1693–8, 1700PubMedGoogle Scholar
  122. 122.
    Borghi J, Guest JF. Economic impact of using mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in the UK. Eur Psychiatry 2000 Sep; 15(6): 378–87PubMedCrossRefGoogle Scholar
  123. 123.
    Romeo R, Patel A, Knapp M, et al. The cost-effectiveness of mirtazapine versus paroxetine in treating people with depression in primary care. Int Clin Psychopharmacol 2004 May; 19(3): 125–34PubMedCrossRefGoogle Scholar
  124. 124.
    Holm KJ, Jarvis B, Foster RH. Mirtazapine: a pharmacoeconomic review of its use in depression. Pharmacoeconomics 2000 May; 17(5): 515–34PubMedCrossRefGoogle Scholar
  125. 125.
    Montgomery SA. Safety of mirtazapine: a review. Int Clin Psychophamacol 1995 Dec; 10 Suppl. 4: 37–45CrossRefGoogle Scholar
  126. 126.
    Biswas PN, Wilton LV, Shakir SA. The pharmacovigilance of mirtazapine: results of a prescription event monitoring study on 13554 patients in England. J Psychopharmacol 2003 Mar; 17(1): 121–6PubMedCrossRefGoogle Scholar
  127. 127.
    Waring WS, Good AM, Bateman DN. Lack of significant toxicity after mirtazapine overdose: a five-year review of cases admitted to a regional toxicology unit. Clin Toxicol (Phila) 2007; 45(1): 45–50CrossRefGoogle Scholar
  128. 128.
    Boyarsky BK, Haque W, Rouleau MR, et al. Sexual functioning in depressed outpatients taking mirtazapine. Depress Anxiety 1999; 9(4): 175–9PubMedCrossRefGoogle Scholar
  129. 129.
    Saiz-Ruiz J, Montes JM, Ibánez A, et al. Assessment of sexual functioning in depressed patients treated with mirtazapine: a naturalistic 6-month study. Hum Psychopharmacol 2005 Aug; 20(6): 435–40PubMedCrossRefGoogle Scholar
  130. 130.
    Osváth P, Fekete S, Voros V, et al. Mirtazapine treatment and sexual functions: results of a Hungarian, multicentre, prospective study in depressed out-patients. Int J Psychiatry Clin Pract 2007 Sep; 11(3): 242–5CrossRefGoogle Scholar
  131. 131.
    Djulus J, Koren G, Einarson TR, et al. Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes. J Clin Psychiatry 2006 Aug; 67(8): 1280–4PubMedCrossRefGoogle Scholar
  132. 132.
    Cobert J, Ferreira GLC, Wilton L, et al. An investigation of the association of white blood cell dyscrasias with the use of mirtazapine compared to the use of other anti-depressants. Drug Saf 2006; 29(10): 921CrossRefGoogle Scholar
  133. 133.
    Papakostas GI, Homberger CH, Fava M. A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. J Psychopharmacol. Epub 2008 Feb 28Google Scholar
  134. 134.
    Gartlehner G, Thieda P, Hansen RA, et al. Comparative risk for harms of second-generation antidepressants: a systematic review and meta-analysis. Drug Saf 2008; 31(10): 851–65PubMedCrossRefGoogle Scholar
  135. 135.
    Rottach KG, Schaner BM, Kirch MH, et al. Restless legs syndrome as side effect of second generation anti-depressants. J Psychiatr Res 2008 Nov; 43(1): 70–5PubMedCrossRefGoogle Scholar
  136. 136.
    Van Der Flier S, Schutte AJ. Tolerability of mirtazapine versus other antidepressants in patients with major depression [abstract no. NR479 plus poster]. American Psychiatric Association 156th Annual Meeting; 2003 May 17—22; San Francisco (CA)Google Scholar
  137. 137.
    Michelson D, Kociban K, Tamura R, et al. Mirtazapine, yohimbine or olanzapine augmentation therapy for serotonin reuptake-associated female sexual dysfunction: a randomized, placebo controlled trial. J Psychiatr Res 2002; 36(3): 147–52PubMedCrossRefGoogle Scholar
  138. 138.
    Gelenberg AJ, McGahuey C, Laukes C, et al. Mirtazapine substitution in SSRI-induced sexual dysfunction. J Clin Psychiatry 2000 May; 61(5): 356–60PubMedCrossRefGoogle Scholar
  139. 139.
    Honig A, Kuyper AM, Schene AH, et al. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosom Med 2007; 69(7): 606–13PubMedCrossRefGoogle Scholar
  140. 140.
    Davidson JRT, Meltzer-Brody SE. The underrecognition and undertreatment of depression: what is the breadth and depth of the problem. J Clin Psychiatry 1999; 60 Suppl. 7: 4–9Google Scholar
  141. 141.
    National Institute for Health and Clinical Excellence. Depression: management of depression in primary and secondary care: quick reference guide (amended) [online]. Available from URL: http://www.nice.org.uk [Accessed 2008 May 27]
  142. 142.
    Fochtmann LJ, Gelenberg AJ. Guideline watch: practice guideline for the treatment of patients with major depressive disorder. 2nd ed. Arlington (VA): American Psychiatric Association, 2005Google Scholar
  143. 143.
    Suehs B, Argo TR, Bendele SD, et al. Texas Medication Algorithm Project procedural manual: major depressive disorder algorithms [online]. Available from URL: http://www.dshs.state.tx.us/mhprograms/pdf/TIMA_MDD_Manual_080608.pdf [Accessed 2009 Mar 5]
  144. 144.
    Ravindran L, Conn D, Ravindran A. Pharmacotherapy of depression in older adults. Geriatrics Aging 2005; 8(8): 20–7Google Scholar

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  • Katherine F. Croom
    • 1
    • 2
  • Caroline M. Perry
    • 1
    • 2
  • Greg L. Plosker
    • 1
    • 2
  1. 1.Wolters Kluwer Health ∣ AdisMairangi Bay, North Shore, AucklandNew Zealand
  2. 2.Wolters Kluwer HealthPhiladelphiaUSA

Personalised recommendations